Search Results

Aspirin Use May Increase Pancreatic Cancer Risk

Contacts: Warren Froelich/AACR215/440-9300/froelich@aacr.org Aimee Frank/Spectrum Science 202/955-6222/amf@spectrumscience.com ASPIRIN USE MAY INCREASE PANCREATIC CANCER RISK Phoenix, AZ – The many health benefits of regular aspirin use have been well-documented, and...

Cancer Tip: Of Asthma and Aspirin, Two Studies Highlight Role of Inflammation in Cancer

Can reducing inflammation keep cancer at bay? Two novel studies presented at the 2007 Annual Meeting of the American Association for Cancer Research that examine use of common anti-inflammatory agents suggest this might be the case. One large study found

Aspirin Use in Relation to Risk of Prostate Cancer

Michael F. Leitzmann, Meir J. Stampfer, Jing Ma, June M. Chan, Graham A. Colditz, Walter C. Willett, Edward Giovannucci

Cancer Epidemiology, Biomarkers And Prevention Vol. 11, 1108-1111, October 2002

ABSTRACT: Experimental studies have shown inhibitory effects of nonsteroidal anti-inflammatory drugs on prostate cancer cell proliferation and reduction of prostate cancer metastasis, suggesting their possible preventive role for prostate cancer. We examined the a

Abstract | FullText

Association of Aspirin and Nonsteroidal Anti-inflammatory Drug Use with Breast Cancer

Trista W. Johnson, Kristin E. Anderson, DeAnn Lazovich, Aaron R. Folsom

Cancer Epidemiology, Biomarkers And Prevention Vol. 11, 1586-1591, December 2002

ABSTRACT: OBJECTIVE: Previous epidemiological studies have suggested that use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with reduced risk of breast cancer, but some studies have been limited in their ability to separate th

Abstract | FullText

Post-Study Aspirin Intake and Factors Motivating Participation in a Colorectal Cancer Chemoprevention Trial

Dory A. Sample, Pamela S. Sinicrope, Michael J. Wargovich, Frank A. Sinicrope

Cancer Epidemiology, Biomarkers And Prevention Vol. 11, 281-285, March 2002

ABSTRACT: We conducted an exploratory, cross-sectional study examining motivators for study participation and post-study aspirin intake in a chemoprevention trial. The parent clinical trial aimed to determine the optimal aspirin dose for colorectal cancer chemopre

Abstract | FullText

Aspirin, NSAIDs, and Colorectal Cancer: Possible Involvement in an Insulin-Related Pathway

Martha L. Slattery, Wade Samowitz, Michael Hoffman, Khi Ne Ma, Theodore R. Levin, Susan Neuhausen

Cancer Epidemiology, Biomarkers And Prevention Vol. 13, 538-545, April 2004

ABSTRACT: Introduction: Aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce risk of colorectal cancer. Although inhibition of cyclooxygenase (COX)-2 is generally thought to be the relevant mechanism, aspirin-like drugs apparently ar

Abstract | FullText

Aspirin Induction of Apoptosis in Esophageal Cancer: A Potential for Chemoprevention

Ming Li, Reuben Lotan, Bernard Levin, Eiichi Tahara, Scott M. Lippman, Xiao-Chun Xu

Cancer Epidemiology, Biomarkers And Prevention Vol. 9, 545-549, June 2000

ABSTRACT: The potential use of non-steroidal anti-inflammatory drugs (NSAIDs) in the prevention of gastrointestinal cancers has been highlighted recently. However, it is not known whether NSAIDs could also be useful for preventing esophageal cancer, although regul

Abstract | FullText

A Novel Mechanism for Aspirin-mediated Growth Inhibition of Human Colon Cancer Cells

Ajay Goel, Dong Kyung Chang, Luigi Ricciardiello, Christoph Gasche, C. Richard Boland

Clinical Cancer Research Vol. 9, 383-390, January 2003

ABSTRACT: PURPOSE: The molecular mechanisms by which aspirin and other nonsteroidal anti-inflammatory drugs exert chemopreventative effects in colon cancer are unclear and complex. Current investigations focus on the chemopreventive properties of nonsteroidal anti

Abstract | FullText

Aspirin is Clinically Effective in Chemoprevention of Colorectal Neoplasia: Point

Moshe Leshno, Menachem Moshkowitz, Nadir Arber

Cancer Epidemiology, Biomarkers And Prevention Vol. 17, 1558-1561, July 2008

ABSTRACT:

Abstract | FullText

Aspirin Should Not Be Promoted for Colon Cancer Prevention: Counterpoint

Robert S. Sandler

Cancer Epidemiology, Biomarkers And Prevention Vol. 17, 1562-1563, July 2008

ABSTRACT:

Abstract | FullText

Men Who Take Aspirin Have Significantly Lower PSA Levels

WASHINGTON, D.C. - The use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is significantly associated with lower PSA levels, especially among men with prostate cancer, say researchers at Vanderbilt University. This large analysis known as the Nashville Men's Health Study...

Stony Brook University Medical Researcher Developing New Medication to Prevent Colon Cancer

Findings on More Potent Aspirin to be Reported at Cancer Research Conference SEATTLE, WASH—A Stony Brook University researcher is testing a new form of aspirin—one that is much more potent than its commercially available counterpart, but with almost none of the side effects—to determine...

Exercise, Aspirin Consumption, and Childbirth May Alter Cancer Risk

Personal choices, such as smoking and consumption of fatty foods, have long been linked to increased cancer risk. During recent years, scientists have been seeking to isolate a variety of lifestyle decisions that may stave off the onset of cancer or even

Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Counterpoint

Janusz Jankowski, Richard Hunt

Cancer Epidemiology, Biomarkers And Prevention Vol. 17, 1858-1861, August 2008

ABSTRACT: Aspirin is the best chemoprevention agent for colorectal cancer risk reduction despite the fact that the evidence for a decrease in mortality is weak. The cyclooxygenase-2 selective agents (COXIBS) have an efficacy similar to that of aspirin for most gas

Abstract | FullText

Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Counterpoint

Janusz Jankowski, Richard Hunt

Cancer Epidemiology, Biomarkers And Prevention Vol. 17, 1858-1861, August 2008

ABSTRACT: Aspirin is the best chemoprevention agent for colorectal cancer risk reduction despite the fact that the evidence for a decrease in mortality is weak. The cyclooxygenase-2 selective agents (COXIBS) have an efficacy similar to that of aspirin for most gas

Abstract | FullText

A Dose-finding Study of Aspirin for Chemoprevention Utilizing Rectal Mucosal Prostaglandin E2 Levels as a Biomarker

Dory Sample, Michael Wargovich, Susan M. Fischer, Nikil Inamdar, Peter Schwartz, Xuemei Wang, Kim-Anh Do, Frank A. Sinicrope

Cancer Epidemiology, Biomarkers And Prevention Vol. 11, 275-279, March 2002

ABSTRACT: Epidemiological and experimental evidence indicates that aspirin can protect against colorectal cancer. Aspirin inhibits cyclooxygenase enzymes and blocks prostaglandin (PG) biosynthesis. Using rectal PGE2 levels as a mucosal biomarker, we sought to dete

Abstract | FullText

A Dose-finding Study of Aspirin for Chemoprevention Utilizing Rectal Mucosal Prostaglandin E2 Levels as a Biomarker

Dory Sample, Michael Wargovich, Susan M. Fischer, Nikil Inamdar, Peter Schwartz, Xuemei Wang, Kim-Anh Do, Frank A. Sinicrope

Cancer Epidemiology, Biomarkers And Prevention Vol. 11, 275-279, March 2002

ABSTRACT: Epidemiological and experimental evidence indicates that aspirin can protect against colorectal cancer. Aspirin inhibits cyclooxygenase enzymes and blocks prostaglandin (PG) biosynthesis. Using rectal PGE2 levels as a mucosal biomarker, we sought to dete

Abstract | FullText

Effect of Aspirin on Prostaglandin E2 Formation and Transforming Growth Factor Expression in Human Rectal Mucosa from Individuals with a History of Adenomatous Polyps of the Colon1

Christopher J. Barnes, Rhoda L. Hamby-Mason, W. Elaine Hardman, Ivan L. Cameron, K. Vincent Speeg, Makau Lee

Cancer Epidemiology, Biomarkers And Prevention Vol. 8, 311-315, April 1999

ABSTRACT: Colorectal cancer is the second-most frequent cause of cancer mortality in the United States. Human epidemiology and laboratory studies indicate that aspirin may be an effective colorectal cancer chemopreventive agent. This study was designed to determin

Abstract | FullText

Reduction of -Catenin/T-Cell Transcription Factor Signaling by Aspirin and Indomethacin Is Caused by an Increased Stabilization of Phosphorylated -Catenin

Susanne Dihlmann, Simone Klein, Magnus von Knebel Doeberitz

Molecular Cancer Theraputics Vol. 2, 509-516, June 2003

ABSTRACT: Constitutive activation of the Wnt/-catenin pathway is thought to play a central role in colorectal carcinogenesis. A key output in this pathway is the nuclear level of -catenin, which determines the transcription of T-cell transcription factor (TCF)/lym

Abstract | FullText

Aspirin Inhibits Tumor Cell Invasiveness Induced by Epstein-Barr Virus Latent Membrane Protein 1 through Suppression of Matrix Metalloproteinase-9 Expression

Shigeyuki Murono, Tomokazu Yoshizaki, Hiroshi Sato, Hajime Takeshita, Mitsuru Furukawa, Joseph S. Pagano

Cancer Research Vol. 60, 2555-2561, May 2000

ABSTRACT: Matrix metalloproteinases (MMPs) are thought to play crucial roles in tumor invasion and metastasis. Because we have shown that EBV latent membrane protein 1 (LMP1) enhances MMP-9 expression by activation of nuclear factor (NF)-B and activator protein (A

Abstract | FullText